You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
An analysis of societal and health system cost-effectiveness and outcomes points to the benefits of expanding pathogenic BRCA1/2 variant testing in six countries.
In Nucleic Acids Research this week: a web platform that combines large molecular and clinical datasets, a web resource for standardized single-cell RNA sequencing data, and more.
In Nature this week: native RNA sequencing and analysis of a human poly(A) transcriptome, nanopore sequencing-based method to analyze short tandem repeat expansions, and more.
Resistance to ash dieback disease among some UK ash trees appears polygenic, the Independent reports.
Researchers documented population structure, ancestry patterns, trait associations, and more with variants found in the genomes of more than 6,400 Ugandans.
Data from more than 11,800 women with breast cancer suggested unselected BRCA1, BRCA2, and PALB2 testing is cost-effective for UK and US payors and societies.
In PNAS this week: genomic turnover among pig ancestors, role of lncRNAs in vaccine-induced immunity, and more.
The article argues that PRS are bad at identifying those who will develop disease but others say this is the same for widely used risk factors.
The thousands of differentially acetylated peaks were enriched in regions harboring genes with disease-related pathology.
The international team of researchers uncovered 535 novel risk loci for blood pressure in its analysis, which drew on more than one million people.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.